In this matched nested case-control study with a long duration of follow-up from blood collection among European men, we found no association of circulating free IGF-I concentration measured using a recently developed ELISA with prostate cancer risk, and these findings did not vary by time to diagnosis or tumor subtype. Here, IGF1 is linked to prostate carcinoma.